{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:06:00Z","timestamp":1779339960596,"version":"3.51.4"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,3,25]],"date-time":"2027-03-25T00:00:00Z","timestamp":1805932800000},"content-version":"am","delay-in-days":297,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["EY031398"],"award-info":[{"award-number":["EY031398"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.exer.2026.110982","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T16:24:10Z","timestamp":1774110250000},"page":"110982","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Metformin inhibits PDGF\u03b2 signaling to suppress hyaluronan and cytokine production in thyroid eye disease"],"prefix":"10.1016","volume":"267","author":[{"given":"Farha","family":"Husain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charkira C.","family":"Patrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Roztocil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven E.","family":"Feldon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7197-5057","authenticated-orcid":false,"given":"Collynn F.","family":"Woeller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exer.2026.110982_bib1","doi-asserted-by":"crossref","first-page":"13613","DOI":"10.1073\/pnas.0405454101","article-title":"Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins","volume":"101","author":"Aoki","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.exer.2026.110982_bib2","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves' ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exer.2026.110982_bib3","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1055\/s-0035-1555762","article-title":"Current insights into the pathogenesis of graves' ophthalmopathy","volume":"47","author":"Bahn","year":"2015","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.exer.2026.110982_bib4","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1002\/ijc.24748","article-title":"Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt","volume":"125","author":"Bai","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.exer.2026.110982_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060184","article-title":"P2X7 integrates PI3K\/AKT and AMPK-PRAS40-mTOR signaling pathways to mediate tumor cell death","volume":"8","author":"Bian","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.exer.2026.110982_bib6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.tem.2017.05.004","article-title":"AMPK as a therapeutic target for treating metabolic diseases","volume":"28","author":"Day","year":"2017","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.exer.2026.110982_bib7","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exer.2026.110982_bib8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/WNO.0000000000001134","article-title":"Teprotumumab in clinical practice: recommendations and considerations from the OPTIC trial investigators","volume":"41","author":"Douglas","year":"2021","journal-title":"J. Neuro Ophthalmol."},{"key":"10.1016\/j.exer.2026.110982_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.739994","article-title":"Orbital signaling in graves' orbitopathy","volume":"12","author":"Draman","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.exer.2026.110982_bib10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrm3507","article-title":"FOXOs: signalling integrators for homeostasis maintenance","volume":"14","author":"Eijkelenboom","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.exer.2026.110982_bib11","doi-asserted-by":"crossref","first-page":"10334","DOI":"10.1074\/jbc.M808848200","article-title":"The transcription of FOXO genes is stimulated by FOXO3 and repressed by growth factors","volume":"284","author":"Essaghir","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.exer.2026.110982_bib12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/acr2.11698","article-title":"Metformin in systemic lupus erythematosus: investigating cardiovascular impact and nephroprotective effects in lupus nephritis","volume":"6","author":"Gonzalez Moret","year":"2024","journal-title":"ACR Open Rheumatol."},{"key":"10.1016\/j.exer.2026.110982_bib13","doi-asserted-by":"crossref","first-page":"18856","DOI":"10.1074\/jbc.M110.179317","article-title":"Peroxisome proliferator-activated receptor gamma ligands inhibit transforming growth factor-beta-induced, hyaluronan-dependent, T cell adhesion to orbital fibroblasts","volume":"286","author":"Guo","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.exer.2026.110982_bib14","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.survophthal.2021.08.010","article-title":"Thinking inside the box: current insights into targeting orbital tissue remodeling and inflammation in thyroid eye disease","volume":"67","author":"Gupta","year":"2022","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.exer.2026.110982_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1167\/iovs.62.1.29","article-title":"MicroRNA-130a is elevated in thyroid eye disease and increases lipid accumulation in fibroblasts through the suppression of AMPK","volume":"62","author":"Hammond","year":"2021","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2026.110982_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ceb.2014.09.004","article-title":"AMPK: positive and negative regulation, and its role in whole-body energy homeostasis","volume":"33","author":"Hardie","year":"2015","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.exer.2026.110982_bib17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrm3311","article-title":"AMPK: a nutrient and energy sensor that maintains energy homeostasis","volume":"13","author":"Hardie","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.exer.2026.110982_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2016.81","article-title":"Regulation and function of AMPK in physiology and diseases","volume":"48","author":"Jeon","year":"2016","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.exer.2026.110982_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21217994","article-title":"Critical role for AMPK in metabolic disease-induced chronic kidney disease","volume":"21","author":"Juszczak","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.exer.2026.110982_bib20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/ICU.0000000000000743","article-title":"Orbital inflammatory disorders: new knowledge, future challenges","volume":"32","author":"Kahana","year":"2021","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.exer.2026.110982_bib21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.intimp.2013.03.020","article-title":"Metformin downregulates Th17 cells differentiation and attenuates murine autoimmune arthritis","volume":"16","author":"Kang","year":"2013","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.exer.2026.110982_bib22","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/bjophthalmol-2015-307399","article-title":"Pathogenesis of thyroid eye disease: review and update on molecular mechanisms","volume":"100","author":"Khong","year":"2016","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2026.110982_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10522-007-9114-6","article-title":"The activation of NF-kappaB through Akt-induced FOXO1 phosphorylation during aging and its modulation by calorie restriction","volume":"9","author":"Kim","year":"2008","journal-title":"Biogerontology"},{"key":"10.1016\/j.exer.2026.110982_bib24","doi-asserted-by":"crossref","first-page":"e1653","DOI":"10.1210\/clinem\/dgab824","article-title":"Inhibition of TSH\/IGF-1 receptor crosstalk by teprotumumab as a treatment modality of thyroid eye disease","volume":"107","author":"Krieger","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.exer.2026.110982_bib25","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.numecd.2015.01.003","article-title":"Type 2 diabetic patients with Graves' disease have more frequent and severe Graves' orbitopathy","volume":"25","author":"Le Moli","year":"2015","journal-title":"Nutr. Metabol. Cardiovasc. Dis."},{"key":"10.1016\/j.exer.2026.110982_bib26","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1006\/abio.1994.1267","article-title":"An agarose gel electrophoretic method for analysis of hyaluronan molecular weight distribution","volume":"219","author":"Lee","year":"1994","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.exer.2026.110982_bib27","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1167\/iovs.15-18157","article-title":"PDGF-BB enhances the proliferation of cells in human orbital fibroblasts by suppressing PDCD4 expression via Up-Regulation of microRNA-21","volume":"57","author":"Lee","year":"2016","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2026.110982_bib28","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1089\/thy.2007.0407","article-title":"Immune mechanisms in thyroid eye disease","volume":"18","author":"Lehmann","year":"2008","journal-title":"Thyroid"},{"key":"10.1016\/j.exer.2026.110982_bib29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3803\/EnM.2024.101","article-title":"The fascinating interplay between growth hormone, insulin-like growth Factor-1, and insulin","volume":"39","author":"Nijenhuis-Noort","year":"2024","journal-title":"Endocrinol. Metab."},{"key":"10.1016\/j.exer.2026.110982_bib30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40199-018-0208-2","article-title":"Effects of metformin on the PI3K\/AKT\/FOXO1 pathway in anaplastic thyroid cancer cell lines","volume":"26","author":"Nozhat","year":"2018","journal-title":"Daru"},{"key":"10.1016\/j.exer.2026.110982_bib31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1167\/iovs.65.13.40","article-title":"Tapinarof, an aryl hydrocarbon receptor ligand, mitigates fibroblast activation in thyroid eye disease: implications for novel therapy","volume":"65","author":"Patrick","year":"2024","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2026.110982_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cells9010184","article-title":"A review of FoxO1-Regulated metabolic diseases and related drug discoveries","volume":"9","author":"Peng","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.exer.2026.110982_bib33","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.bcp.2019.07.010","article-title":"Blood-retinal barrier protection against high glucose damage: the role of P2X7 receptor","volume":"168","author":"Platania","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.exer.2026.110982_bib34","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.4103\/ijo.IJO_1443_19","article-title":"Severity of thyroid eye disease and type-2 diabetes mellitus: is there a correlation?","volume":"68","author":"Ramamurthy","year":"2020","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.exer.2026.110982_bib35","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1089\/thy.2024.0529","article-title":"Targeting the aryl hydrocarbon receptor to attenuate IGF1R signaling in thyroid eye disease","volume":"35","author":"Roztocil","year":"2025","journal-title":"Thyroid"},{"key":"10.1016\/j.exer.2026.110982_bib36","doi-asserted-by":"crossref","first-page":"36916","DOI":"10.1074\/jbc.M301598200","article-title":"Tumor necrosis factor-alpha-induced IKK phosphorylation of NF-kappaB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway","volume":"278","author":"Sakurai","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.exer.2026.110982_bib37","article-title":"Comparison of treatment cost and quality-of-life impact of thyroid eye disease therapies","volume":"63","author":"Shah","year":"2022","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2026.110982_bib38","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.beem.2011.10.002","article-title":"Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy","volume":"26","author":"Smith","year":"2012","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.exer.2026.110982_bib39","first-page":"167","article-title":"Building the case for insulin-like growth factor Receptor-I involvement in thyroid-associated ophthalmopathy","volume":"7","author":"Smith","year":"2016","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.exer.2026.110982_bib40","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exer.2026.110982_bib41","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/973986","article-title":"Metformin attenuates experimental autoimmune arthritis through reciprocal regulation of Th17\/Treg balance and osteoclastogenesis","volume":"2014","author":"Son","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.exer.2026.110982_bib42","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1016\/S2665-9913(20)30004-7","article-title":"Safety and efficacy of metformin in systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"2","author":"Sun","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.exer.2026.110982_bib43","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41574-019-0305-4","article-title":"New insights into the pathogenesis and nonsurgical management of Graves orbitopathy","volume":"16","author":"Taylor","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.exer.2026.110982_bib44","doi-asserted-by":"crossref","first-page":"E944","DOI":"10.1210\/jc.2012-1020","article-title":"PDGF enhances orbital fibroblast responses to TSHR stimulating autoantibodies in Graves' ophthalmopathy patients","volume":"97","author":"van Steensel","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.exer.2026.110982_bib45","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1167\/iovs.09-4338","article-title":"Platelet-derived growth factor-BB: a stimulus for cytokine production by orbital fibroblasts in Graves' ophthalmopathy","volume":"51","author":"van Steensel","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2026.110982_bib46","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1167\/iovs.08-2443","article-title":"Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves' ophthalmopathy","volume":"50","author":"van Steensel","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2026.110982_bib47","doi-asserted-by":"crossref","first-page":"7917","DOI":"10.1074\/jbc.M110.193656","article-title":"Hyaluronan synthesis is inhibited by adenosine monophosphate-activated protein kinase through the regulation of HAS2 activity in human aortic smooth muscle cells","volume":"286","author":"Vigetti","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.exer.2026.110982_bib48","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000367968","article-title":"Platelet-derived growth factor: a key factor in the pathogenesis of graves' ophthalmopathy and potential target for treatment","volume":"3","author":"Virakul","year":"2014","journal-title":"Eur. Thyroid J."},{"key":"10.1016\/j.exer.2026.110982_bib49","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.celrep.2019.09.070","article-title":"Metformin improves mitochondrial respiratory activity through activation of AMPK","volume":"29","author":"Wang","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.exer.2026.110982_bib50","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2213-8587(16)30046-8","article-title":"Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy","volume":"5","author":"Wiersinga","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.exer.2026.110982_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415508","article-title":"Metformin attenuates inflammation and fibrosis in thyroid-associated ophthalmopathy","volume":"23","author":"Xu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.exer.2026.110982_bib52","doi-asserted-by":"crossref","first-page":"136","DOI":"10.5483\/BMBRep.2021.54.2.178","article-title":"Ganglioside GT1b increases hyaluronic acid synthase 2 via PI3K activation with TLR2 dependence in orbital fibroblasts from thyroid eye disease patients","volume":"54","author":"Yoo","year":"2021","journal-title":"BMB Rep."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483526001387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483526001387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:09:57Z","timestamp":1779336597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483526001387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":52,"alternative-id":["S0014483526001387"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2026.110982","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metformin inhibits PDGF\u03b2 signaling to suppress hyaluronan and cytokine production in thyroid eye disease","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2026.110982","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110982"}}